South Korea To Double Tamiflu Supply To Block Bird Flu
This article was originally published in PharmAsia News
Executive SummarySouth Korea plans to double its Tamiflu (oseltamivir phosphate) stockpile by the end of this year, giving it 2.5 million doses of Roche's bird flu drug. The government estimates a supply that large could treat about 5 percent of the population. The administration made the decision at a Cabinet meeting that also cemented plans to establish a task force of several ministries to prevent an outbreak of bird flu. The plans were adopted in the wake of the country's first case of the avian influenza in April. (Click here for more
You may also be interested in...
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced January 2020.
Industry experts expect a continued uptick in deals valued between $2bn-$10bn this year as buyers look to add critical mass in areas like oncology, rare disease and cell and gene therapy. Divestitures to free up capital and narrow focus should continue too.
UK-centric investment firm Syncona’s model of “founding, building and funding” early-stage biotech companies – with a commitment to the longer term – hopes to help make Great Britain a cell and gene therapy powerhouse.